{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:57Z","timestamp":1793037717919,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.eururo.2008.06.070","type":"journal-article","created":{"date-parts":[[2008,6,27]],"date-time":"2008-06-27T08:57:37Z","timestamp":1214557057000},"page":"1066-1072","source":"Crossref","is-referenced-by-count":140,"title":["Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate"],"prefix":"10.1016","volume":"54","author":[{"given":"Christian","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Al-Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut A.","family":"Gr\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim W.","family":"Th\u00fcroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Zinser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinold","family":"Gamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.06.070_bib1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0090-4295(99)80250-7","article-title":"Geographical and temporal patterns of incidence and mortality from prostate cancer","volume":"46","author":"Boyle","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.06.070_bib2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","article-title":"EAU guidelines on prostate cancer","volume":"53","author":"Heidenreich","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2008.06.070_bib4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2008.06.070_bib5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1634\/theoncologist.7-4-360","article-title":"State-of-the-art treatment of metastatic hormone-refractory prostate cancer","volume":"7","author":"Goodin","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2008.06.070_bib6","doi-asserted-by":"publisher","unstructured":"Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006250.","DOI":"10.1002\/14651858.CD006250"},{"key":"10.1016\/j.eururo.2008.06.070_bib7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.eururo.2007.02.060","article-title":"Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study","volume":"52","author":"Di Lorenzo","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.eururo.2007.03.029","article-title":"New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?","volume":"52","author":"Sciarra","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1016\/j.eururo.2008.06.070_bib10","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2008.06.070_bib11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2005.09.021","article-title":"Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer","volume":"49","author":"Hikosaka","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.eururo.2005.12.045","article-title":"Natural history and treatment of bone complications in prostate cancer","volume":"49","author":"Saad","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.eururo.2007.02.033","article-title":"Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression","volume":"52","author":"Lein","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.070_bib14","first-page":"6","article-title":"Bisphosphonate und ihre h\u00e4ufigsten Nebenwirkungen","author":"Diel","year":"2005","journal-title":"Journal Onkologie"},{"key":"10.1016\/j.eururo.2008.06.070_bib15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2008.06.070_bib16","first-page":"398","article-title":"Osteonecrosis of the jaws following treatment with bisphosphonates\u2014own study","volume":"6","author":"Walter","year":"2007","journal-title":"Czas Stomatol"},{"key":"10.1016\/j.eururo.2008.06.070_bib17","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","article-title":"Avascular necrosis of the jaws: risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2008.06.070_bib18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00066-007-1666-5","article-title":"Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases","volume":"183","author":"Gr\u00f6tz","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.eururo.2008.06.070_bib19","doi-asserted-by":"publisher","unstructured":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369\u201376.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"10.1016\/j.eururo.2008.06.070_bib20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis","volume":"15","author":"Walter","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2008.06.070_bib21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2008.06.070_bib22","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2008.06.070_bib23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2008.06.070_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/mol.59.2.193","article-title":"Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation","volume":"59","author":"Reszka","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.eururo.2008.06.070_bib25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1177\/154405910708601101","article-title":"Osteonecrosis of the jaws and bisphosphonate therapy","volume":"86","author":"Ruggiero","year":"2007","journal-title":"J Dent Res"},{"key":"10.1016\/j.eururo.2008.06.070_bib26","first-page":"10","article-title":"Zahn\u00e4rztliche Betreuung von Patienten unter\/nach Bisphosphonat-Medikation","volume":"60","author":"Gr\u00f6tz","year":"2006","journal-title":"DZZ"},{"key":"10.1016\/j.eururo.2008.06.070_bib27","unstructured":"Saarland Ministerium f\u00fcr Justiz GuS. 40 jahre epidemiologisches Krebsregister Saarland 1967-2007: dokumentieren, informieren, evaluieren. 2007."},{"key":"10.1016\/j.eururo.2008.06.070_bib28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2008.06.070_bib29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.eururo.2008.06.070_bib30","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.06.070_bib31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2008.06.070_bib32","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1200\/JCO.2005.11.676","article-title":"Avascular necrosis of femoral and\/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy","volume":"23","author":"Talamo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2008.06.070_bib33","first-page":"E351","article-title":"Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid","volume":"12","author":"Garcia Saenz","year":"2007","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.eururo.2008.06.070_bib34","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.eururo.2008.06.070_bib35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2008.06.070_bib36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228380800777X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228380800777X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T18:08:21Z","timestamp":1631470101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228380800777X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S030228380800777X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.06.070","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}